Ding et al. [15] studied the activation of tumor candidate suppressor 3 (TUSC3) as a possible therapeutic therapy for XMEN patients. This evidence concerns the gene TUSC3 and X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia.